Accession Number:

ADA383150

Title:

The Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer

Descriptive Note:

Annual rept. 1 Jun 1999-31 May 2000

Corporate Author:

HEALTH RESEARCH INC BUFFALO NY

Personal Author(s):

Report Date:

2000-06-01

Pagination or Media Count:

24.0

Abstract:

The work outlined in the original grant proposal was designed to develop new breast cancer treatments that combined a current breast cancer chemotherapy doxorubicin and Doxil and a cytokine-based immunotherapy IL-l2 and IL-2 with fever-like whole body hyperthermia WBH. We have found that the combination of WBH with Doxil does indeed result in a better anti-tumor effect in our SCID mouse human breast tumor xenograft model when compared to Doxil alone. Experiments examining free Doxorubicin are underway. Additional work has shown that free lL-l2 when used in combination with WBH only marginally enhances the anti- tumor response when compared to the IL-l2 alone in our model. We feel that this is due to the lack of T and B cells in the SCID mice that may have inhibited our cytokine immunotherapy protocol. Therefore additional experiments have been executed using a different model BALEc mice bearing Colon 26 tumors while a more appropriate breast cancer model can be developed. Data using this model have been extremely promising when using both free IL-l2 and polylactic acid microsphere encapsulated IL-l2. Overall, the results generated the past year have been promising.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE